In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
How ketamine therapy helped this Canadian veteran Read More »
While we suspected that psilocybin might perform well compared to the SSRI, we had not expected it to perform as well as it did. In fact, the initial main hypothesis for this trial was that the psilocybin therapy would have superior effects on psychological wellbeing, but not on depression severity scores. This prediction was generally supported, but people in the psilocybin group also showed evidence of greater improvements across most depression measures, as well as anxiety symptoms, work and social functioning, suicidal feelings and the ability to feel emotion and pleasure.
Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.
Trial of Psilocybin versus Escitalopram for Depression Read More »
Roger S. McIntyre, M.D., Joshua D. Rosenblat, M.D., M.Sc., Charles B. Nemeroff, M.D., Ph.D., Gerard Sanacora, M.D., Ph.D., James W. Murrough, M.D., Ph.D., Michael Berk, Ph.D., M.B.B.Ch., Elisa Brietzke, M.D., Ph.D., Seetal Dodd, Ph.D., Philip Gorwood, M.D., Ph.D., Roger Ho, M.D., M.B.B.S., Dan V. Iosifescu, M.D., Carlos Lopez Jaramillo, M.D., Ph.D., Siegfried Kasper, M.D., Kevin
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
‘The ketamine blew my mind’: can psychedelics cure addiction and depression? Read More »
Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Comparative Efficacy of Racemic Ketamine and Esketamine for Depression Read More »
Hamilton Morris spent 3 days with Dr. Raquel Bennett (founder of KRIYA Institute) talking about therapeutic ketamine. Filmed in Hillsborough, CA in July 2017.
Hamilton’s Pharmacopeia – Ketamine – Season 2 Episode 5 Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Repeated ketamine infusions reduce PTSD symptom severity Read More »
Sub-anaesthetic doses of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist provide rapid and long-lasting antidepressant effects in these patients, but the molecular mechanism of these effects remains unclear.
Antidepressant Actions of Ketamine Engage Cell-Specific Translation via eIF4E Read More »
Hartej Gill, Barjot Gill, Nelson B. Rodrigues, Orly Lipsitz, Joshua Daniel Rosenblat, Sabine El-Halabi, Flora Nasri, Rodrigo B. Mansur, Yena Lee, Roger S. McIntyre Published 23 November 2020 | https://doi.org/10.1016/j.neubiorev.2020.11.020 Abstract Replicated evidence has documented cognitive deficits in populations with treatment-resistant depression (TRD). Approximately 40 % of patients with MDD present with impairment of one